Skip to main content
. 2021 Mar 11;13(3):904. doi: 10.3390/nu13030904

Figure 4.

Figure 4

Effect of chronic oral administration of Safr’InsideTM (6.25 mg/Kg) on depressive-like behavior measured in the FST. (a) Immobility time; (b) Index of immobility; (c) Swimming time and (d) Climbing time. FST has been conducted after 4 weeks of treatment and 3 h after the last gavage. Results are shown as mean ± SEM. Control (Water): n = 8; Safr’Inside: n = 9.